96 related articles for article (PubMed ID: 10185838)
1. "Guidance for industry: current good manufacturing practice for blood and blood components: (1). Quarantine and disposition of units from prior collections from donors with repeatedly reactive screening test for antibody to hepatitis C virus (anti-HCV); (2). Supplemental testing, and the notification of consignees and blood recipients of donor test results for anti-HCV;" availability--FDA. Notice.
Fed Regist; 1998 Oct; 63(203):56198-9. PubMed ID: 10185838
[TBL] [Abstract][Full Text] [Related]
2. Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Aug; 72(164):48765-801. PubMed ID: 17886394
[TBL] [Abstract][Full Text] [Related]
3. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
[TBL] [Abstract][Full Text] [Related]
4. Medicare and Medicaid programs; hospital conditions of participation: laboratory services. Interim final rule with comment period.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2007 Aug; 72(164):48562-74. PubMed ID: 17886393
[TBL] [Abstract][Full Text] [Related]
5. Guidance for industry: donor screening for antibodies to HTLV-II; availability--FDA. Notice.
Fed Regist; 1998 Sep; 63(188):51942-3. PubMed ID: 10185814
[TBL] [Abstract][Full Text] [Related]
6. Interim recommendations for deferral of donors at increased risk for HIV-1 Group O infection; guidance document; availability--FDA. Notice.
Fed Regist; 1997 Sep; 62(184):49695. PubMed ID: 10173802
[TBL] [Abstract][Full Text] [Related]
7. New Federal guidelines for hepatitis C virus lookback.
Witthaus D
MLO Med Lab Obs; 1998 Sep; 30(9):22-6. PubMed ID: 10186315
[TBL] [Abstract][Full Text] [Related]
8. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.
Kleinman SH; Stramer SL; Brodsky JP; Caglioti S; Busch MP
Transfusion; 2006 May; 46(5):695-702. PubMed ID: 16686836
[TBL] [Abstract][Full Text] [Related]
9. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
[TBL] [Abstract][Full Text] [Related]
10. Revised precautionary measures to reduce the possible transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products; guidance document; availability--FDA. Notice.
Fed Regist; 1997 Sep; 62(184):49694-5. PubMed ID: 10173801
[TBL] [Abstract][Full Text] [Related]
11. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen.
Katz L; Strong DM; Tegtmeier G; Stramer S
Transfusion; 2008 Nov; 48(11):2315-22. PubMed ID: 18647367
[TBL] [Abstract][Full Text] [Related]
12. A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing.
Shan H; Ren FR; Zhao HY; Zhang YZ; Wen GX; Yao FZ; Gao GJ; Yan LX; Jiang CF; Bai XH; Tiemuer MH; Tu YQ; Zhu FM; Zheng YR; Cui L; Liu CL; Gong XY; Lv QS; Zheng P; Ziermann R; Ness P; Wang JX
Transfusion; 2007 Nov; 47(11):2011-6. PubMed ID: 17958529
[TBL] [Abstract][Full Text] [Related]
13. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
[TBL] [Abstract][Full Text] [Related]
14. Recent Canadian experience with targeted hepatitis C virus lookback.
Goldman M; Patterson L; Long A
Transfusion; 2006 May; 46(5):690-4. PubMed ID: 16686835
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C lookback in Canada.
Goldman M; Long A
Vox Sang; 2000; 78 Suppl 2():249-52. PubMed ID: 10938962
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors.
Hladik W; Kataaha P; Mermin J; Purdy M; Otekat G; Lackritz E; Alter MJ; Downing R
Trop Med Int Health; 2006 Jun; 11(6):951-4. PubMed ID: 16772018
[TBL] [Abstract][Full Text] [Related]
17. Blood recipient notification for hepatitis C in Prince Edward Island.
Van Til LD; Sweet LE
CMAJ; 2000 Jan; 162(2):199-202. PubMed ID: 10674052
[TBL] [Abstract][Full Text] [Related]
18. Risk of transfusion-transmitted hepatitis C virus in a tertiary hospital in Nigeria.
Imarengiaye CO; Enosolease ME; Iribhogbe PE; Ehigiegba AE
Public Health; 2006 Mar; 120(3):274-8. PubMed ID: 16364383
[TBL] [Abstract][Full Text] [Related]
19. "Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and for the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use;'" availability. Food and Drug Administration, HHS. Notice.
Fed Regist; 1999 May; 64(89):25049-50. PubMed ID: 10558535
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the impact of public health notification of suspected transfusion-transmissible hepatitis C virus infection and effectiveness of lookback and traceback investigations by Canadian Blood Services in British Columbia, Canada, August 2002 through February 2005.
Whitlock M; Lord S; Buxton JA; Doyle P; Bigham M
Transfusion; 2007 Aug; 47(8):1534-9. PubMed ID: 17655599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
